PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
AffiliationDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
MetadataShow full item record
AbstractPoly(ADP-ribose) polymerase inhibitors (PARPi) have changed the management of high-grade serous ovarian cancer (HGSOC). The rationale for the development of PARPi was based on the concept of synthetic lethality, in which a cell can survive a deficiency of one gene/gene product, but may die if there is a deficiency in a combination of genes/gene products. In women with BRCA1/2 deficiency within their ovarian cancer tissue, inhibition of PARP imposes an intolerable burden of DNA damage repair deficiency and may induce cell death.
CitationPARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. 2018, 81(4): 647-658 Cancer Chemother Pharmacol
JournalCancer Chemotherapy and Pharmacology